Skip to main content

Table 1 Characteristics of patients taking standard (150 mg) or reduced (75 mg) dose dabigatran

From: Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses

 Reduced dose (75 mg twice daily)Standard Dose (150 mg twice daily)P-value
Total number of patients14556580 
Age Category, years  < 0.001
 65–697.1%18.0% 
 70 to 7413.7%26.8% 
 75 to 7918.8%25.4% 
 80 to 8426.0%18.1% 
 85 to 8916.8%7.1% 
 90 or over17.5%4.7% 
Sex  < 0.001
 Female56.3%47.9% 
 Male43.7%52.1% 
Race Category  < 0.001
 White84.1%87.5% 
 Black10.2%6.9% 
 Hispanic2.5%1.7% 
 Asian1.4%0.6% 
 Other1.9%3.2% 
 Smoking14.0%16.7%0.01
 Alcohol use2.0%2.3%< 0.001
Weight Category (based on ICD-9 and ICD-10 codes for BMI Category)  < 0.001
 Under-Weight1.2%0.6% 
 Healthy or Overweight10.1%8.0% 
 Obese or Severe Obese20.1%23.9% 
 Not available68.5%67.5% 
Comorbid Conditions
 Prior Stroke26.8%24.4%0.06
 Prior major bleeding from Diagnosis26.7%24.5%0.07
 Gastrointestinal bleeding013.0%0.24
 Cerebral bleeding00.8%0.7
 Diabetes50.7%48.9%0.2
 Prior AMI8.0%5.2%< 0.001
 Liver Disease3.4%2.6%0.13
 Heart Failure48.6%31.3%< 0.001
 Hypertension96.0%93.4%< 0.001
 Ischemic cardiomyopathy55.5%48.0%< 0.001
 Pulmonary16.6%11.4%< 0.001
 COPD36.4%31.8%< 0.001
 Transfusion from Procedure3.8%2.7%0.02
 Revascularization17.3%15.0%0.03
 Implantable Devices16.9%13.8%0.002
 Valve Disease44.7%40.3%0.002
Renal Disease (ICD-9 and ICD-10 codes)  < 0.001
 None or Mild (Stage I, II)53.4%81.7% 
 Moderate (Stage III)36.0%16.5% 
 Severe (Stage IV, V)10.6%1.7% 
Concurrent Drugs (+/− 90 days of initiating DOAC)
 SSRI/SNRI33.5%31.0%0.05
 Strong and moderate P-GP inhibitors21.4%22.7%0.28
 P-GP inducers16.4%18.8%0.03
 Strong P-GP and CYP3A4 dual inhibitors22.7%22.5%0.8
 P-GP and CYP3A4 inducers16.4%18.8%0.03
 ACE inhibitors70.1%68.0%0.12
 Warfarin20.8%25.0%< 0.001
 Angiotensin receptor blockers41.0%39.3%0.2
 Beta blockers92.1%89.1%< 0.001
 Calcium channel blockers66.8%63.8%0.03
 Digoxin31.1%29.4%0.2
 Proton pump inhibitors60.5%56.4%0.004
 NSAIDs49.6%51.2%0.29
 Antiplatelets32.0%26.5%< 0.001
 Insulin17.0%12.9%< 0.001
 Statins79.6%79.4%0.86
 Antiarrhythmics47.3%48.0%0.6
Estimated Glomerular Filtration rate (ml/min/1.73 m2)  < 0.001
  < 3012.3%2.5% 
 30–6062.2%45.8% 
 60–9023.8%46.0% 
> = 901.8%5.7% 
CCI(Charlson Comorbodity Index), mean (standard deviation)5.52 (3.75)4.17(3.47)< 0.001
  1. Abbreviations: ACE Angiotensin converting enzyme, AMI Acute myocardial infarction, COPD Chronic obstructive pulmonary disease, ICD International classification of diseases, NSAIDS Non-steroidal antiinflammatory drugs, P-GP P-glycoprotein, CYP Cytochrome